Multipotency of Flk1+CD34- progenitors derived from human fetal bone marrow
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing Road 288, Tianjin 300020, People's Republic of China. Journal of Laboratory and Clinical Medicine
(Impact Factor: 2.8).
05/2004; 143(4):230-40. DOI: 10.1016/j.lab.2003.11.008
We report that a cell population derived from human fetal bone marrow, termed Flk1+CD34- multipotent stem cells, can differentiate not only into osteogenic, adipogenic, and endothelial lineages but also into hepatocyte-like cells and neural and erythroid cells at the single-cell level. We depleted mononuclear cells from fetal bone marrow of CD45+, GlyA+, and CD34+ cells with the use of micromagnetic beads, then cultured them by limiting dilution. Three single colonies were harvested, expanded, and characterized. The clones have been expanded for more than 50 cell doublings, and cell-doubling time was about 30 hours. About 90% cells were in the G(0)/G(1) phase of the cell cycle, and the cells from the single colony maintained Flk1+ and CD34-. Because fetal bone marrow-derived Flk1+CD34-multipotent stem cells have the capacity for self-renewal and multilineage differentiation even after being expanded for more than 50 cell doublings, they may be an ideal source of stem cells for the treatment of inherited or degenerative diseases.
Available from: boar.or.kr
- "and precise conditions are described elsewhere (Seta et al. 1999; Zheng et al. 2000; Fang et al. 2005). The reaction products were resolved by electrophoresis on a 1.5% agarose gel and visualized with ethidium bromide. "
[Show abstract] [Hide abstract]
ABSTRACT: Mesenchymal stem cells (MSCs) are capable of self-renewing and differentiating into multiple tissues; they are expected to become a source of cells for regenerative therapy. Compared to allogeneic MSCs, autologous MSCs from patients needing cell-based therapy may be an ideal alternative stem cell source. However, characterizations of MSCs from a disease state remains extremely limited. Therefore, we have isolated and characterized MSCs from Parkinson's disease (PD) patients and compared them with MSCs derived from normal adult bone marrow. Our results show that PD-derived MSCs are similar to normal MSCs in phenotype, morphology, and multidifferentiation capacity. Moreover, PD-derived MSCs are capable of differentiating into neurons in a specific medium with up to 30% having the characteristics of dopamine cells. At last, PD-derived MSCs could inhibit T-lymphocyte proliferation induced by mitogens. These findings indicate that MSCs derived from PD patients' bone marrow may be a promising cell type for cellular therapy and somatic gene therapy applications.
In Vitro Cellular & Developmental Biology - Animal 05/2008; 44(5-6):169-77. DOI:10.1007/s11626-008-9093-1 · 1.15 Impact Factor
Available from: ncbi.nlm.nih.gov
- "Therefore, it is of great importance for scientists to find adult stem cells that have a similar differentiation potential to embryonic stem cells. Researchers led by Zhao at the Chinese Academy of Medical Sciences reported that a cell population derived from human foetal bone marrow, termed Flk1 C CD31 K CD34 K stem cells, could differentiate, not only into osteogenic, adipogenic and endothelial lineages, but also hepatocyte-like, neural and erythroid cells at the single-cell level (Fang et al. 2003, 2004). Zhao et al. used cells from a single colony, which precluded the possibility of contamination by different stem cells. "
[Show abstract] [Hide abstract]
ABSTRACT: In the past 5 years, China has increased its efforts in the field of stem cell research and practice. Basic research mainly focuses on bone marrow and embryonic stem cells. Clinical applications of stem cells in the treatment of acute heart failure, acute liver failure and lower limb ischaemia have been reported by many hospitals. China enacted its 'Ethical Guidelines for Human Embryonic Stem Cell Research' in 2003. At present, China has the most liberal and favourable environments for human embryonic stem cell research.
Philosophical Transactions of The Royal Society B Biological Sciences 07/2007; 362(1482):1107-12. DOI:10.1098/rstb.2007.2037 · 7.06 Impact Factor
Available from: Ying Cao
- "Results showed that adherent Flk1 + CD31 À CD34 À cells can also be isolated from adipose tissue and be continuously passaged for at least 20 passages. The morphology , phenotype, and in vitro differentiation potential of the ADAS cells are similar to those of fetal BM-derived Flk1 + CD31 À CD34 À MSCs  . They could differentiate into osteogenic and adipogenic cells in vitro. "
[Show abstract] [Hide abstract]
ABSTRACT: In this study, we isolated CD31(-), CD34(-), CD106(-) (VCAM-1(-)), and fetal liver kinase(+) (Flk1(+)) cells from adipose tissue. These cells can be induced to differentiate into cells of osteogenic and adipogenic lineages in vitro and were termed adipose derived adult stem cells (ADAS cells). We also showed that they have characteristics of endothelial progenitor cells. In vitro, ADAS cells expressed endothelial markers when cultured with VEGF. In vivo, ADAS cells can differentiate in response to local cues into endothelial cells that contributed to neoangiogenesis in hindlimb ischemia models. PI3 kinase inhibitor LY294002 blocked the differentiation of ADAS cells into endothelial cells in vitro. Because ADAS cells can be expanded in culture without obvious senescence for more than 20 population doublings, they may be a potential source of endothelial cells for cellular pro-angiogenic therapies.
Biochemical and Biophysical Research Communications 08/2005; 332(2):370-9. DOI:10.1016/j.bbrc.2005.04.135 · 2.30 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.